Johnson & Johnson Offers $5.5 Billion to Resolve Talc Cancer Litigation
Johnson & Johnson has put forward a settlement offer totalling $5.5 billion to conclude nearly all outstanding claims related to its talc-based products. The company faces allegations that its baby powder and other talc items contributed to ovarian cancer and mesothelioma in consumers.
Years of Litigation and Controversy
This proposed resolution would address approximately 99.75% of the pending lawsuits. The pharmaceutical giant has been embroiled in this legal battle for years, having previously attempted to resolve the issue through a controversial bankruptcy manoeuvre in 2021. That attempt saw the creation of a subsidiary, LTL Management, which subsequently filed for Chapter 11 bankruptcy, intending to offload the substantial litigation costs. This strategy was ultimately rejected by US courts earlier this year, ruling that the subsidiary was not in genuine financial distress.
Johnson & Johnson maintains that its talc products are safe and do not contain asbestos, a known carcinogen, asserting that decades of independent scientific analysis support this position. Despite this, the company ceased global sales of its talc-based baby powder in 2023, transitioning to a cornstarch-based alternative.
Financial Implications and Shareholder Reaction
The company announced that the $5.5 billion fund would be disbursed over 25 years. This sum includes $2 billion already allocated through the previous bankruptcy filing. Erik Haas, Johnson & Johnson's worldwide vice-president of litigation, stated the settlement would provide “fair and certain compensation” to claimants while allowing the company to focus on its core business. The stock price of Johnson & Johnson saw a marginal increase following the announcement of the proposed settlement, indicating a cautious optimism among investors regarding the potential resolution of this protracted legal saga.
